Streetbeat News

Price Targets

RXRX

Morgan Stanley analyst Vikram Purohit maintains an Equal-Weight rating on Recursion Pharmaceuticals (NASDAQ:RXRX) and raises the price target from $8 to $11.

Portfolio Pulse from Benzinga Newsdesk

July 13, 2023 | 1:55 pm

NAVI

Morgan Stanley analyst Jefferson Harralson has maintained an Equal-Weight rating on Navient (NASDAQ:NAVI) and raised the price target from $17 to $18.

Portfolio Pulse from Benzinga Newsdesk

July 13, 2023 | 1:53 pm

NDAQ

Morgan Stanley analyst Michael Cyprys has maintained an Equal-Weight rating on Nasdaq (NASDAQ:NDAQ) but lowered the price target from $60 to $55.

Portfolio Pulse from Benzinga Newsdesk

July 13, 2023 | 1:52 pm

ELV

UBS analyst Kevin Caliendo maintains a Buy rating on Elevance Health (NYSE:ELV) but lowers the price target from $610 to $575.

Portfolio Pulse from richadhand@benzinga.com

July 13, 2023 | 1:51 pm

MUR

Morgan Stanley analyst Devin McDermott has maintained an Equal-Weight rating on Murphy Oil (NYSE:MUR) and lowered the price target from $44 to $43.

Portfolio Pulse from Benzinga Newsdesk

July 13, 2023 | 1:50 pm

META

Morgan Stanley analyst Brian Nowak has maintained an 'Overweight' rating on Meta Platforms (NASDAQ:META) and raised the price target from $300 to $350.

Portfolio Pulse from Benzinga Newsdesk

July 13, 2023 | 1:49 pm

CI

UBS analyst Kevin Caliendo maintains a Buy rating on Cigna Group (NYSE:CI) but lowers the price target from $375 to $355.

Portfolio Pulse from richadhand@benzinga.com

July 13, 2023 | 1:49 pm

MKTX

Morgan Stanley analyst Michael Cyprys has maintained an Equal-Weight rating on MarketAxess Holdings (NASDAQ:MKTX) and lowered the price target from $339 to $308.

Portfolio Pulse from Benzinga Newsdesk

July 13, 2023 | 1:48 pm

ALHC

UBS analyst Kevin Caliendo maintains a Neutral rating on Alignment Healthcare (NASDAQ:ALHC) and lowers the price target from $8 to $6.

Portfolio Pulse from richadhand@benzinga.com

July 13, 2023 | 1:48 pm

LCID

Morgan Stanley analyst Adam Jonas has reiterated an Underweight rating on Lucid Group (NASDAQ:LCID), maintaining a $5 price target.

Portfolio Pulse from Benzinga Newsdesk

July 13, 2023 | 1:47 pm